Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

Yunlin Zhang(Hospital of the University of Pennsylvania), Marco Ruella(University of Pennsylvania), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Yoon Lee(Advanced Biomass R&D Center (South Korea)), Ruchi P. Patel(Parker Institute for Cancer Immunotherapy), Alberto Carturan(Hospital of the University of Pennsylvania), Dok Hyun Yoon(Asan Medical Center), Soohwan Kim(Dong-A University), Mathew G. Angelos(University of Pennsylvania), Seong Hyun Jeong(Ajou University Hospital), Ji Hyun Lee(JW Pharmaceutical (South Korea)), Jong-Seo Lee(Advanced Biomass R&D Center (South Korea)), Jae‐Cheol Jo(Ulsan College), Guido Ghilardi(Hospital of the University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), Yoon Seok Choi(Ajou University Hospital), Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), LeiGuang Cui, Jong Hyun Cho(Rutgers, The State University of New Jersey), Junho Chung(Seoul National University Hospital), Patrizia Porazzi(Sidney Kimmel Cancer Center), Sung Yong Oh(Dong-A University), Raymone Pajarillo(Hospital of the University of Pennsylvania), Hyungwoo Cho(Ulsan College), Michael Wang(The University of Texas MD Anderson Cancer Center), Sung‐Min Kim(Dong-A University), Sung Hyun Kim(Celltrion (South Korea)), Ki Hyun Kim(Sungkyunkwan University), Ji‐Ho Park(Gyeongsang National University), Yongjun Lee(Bucheon University), Jong‐Hoon Kim(Pohang University of Science and Technology), Hyun‐Jong Lee, Dongfang Liu(Rutgers, The State University of New Jersey), Young‐Ha Lee(Chungnam National University), In-Sik Hwang, Yong Gu Lee(Parker Institute for Cancer Immunotherapy), Ivan Cohen(Hospital of the University of Pennsylvania), Taebum Lee
Molecular Cancer
December 9, 2023
Cited by 32


Related Papers